(Q44622615)

English

Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma

scientific article published on September 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma (English)

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

1 reference

based on heuristic

inferred from title

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Roswitha Forstpointner

6

object named as

Roswitha Forstpointner

0 references

author name string

Andrew Grigg

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Philippe Solal-Celigny

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Peter Hoskin

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Kerry Taylor

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Andrew McMillan

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pamela Bacon

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jennifer Renwick

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Wolfgang Hiddemann

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

International Study Group

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14565651

22 March 2024

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

http://www.tandfonline.com/doi/pdf/10.1080/1042819031000103953

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1503-1508

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000103953

21 January 2018

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

2

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

3

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis

5

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

6

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

7

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

10

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

11

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma

15

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma

18

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL)

19

1 reference

10.1080/1042819031000103953

https://api.crossref.org/works/10.1080/1042819031000103953

22 March 2024

Identifiers

10.1080/1042819031000103953

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44622615&oldid=2108557855"